{"id":"bimervax","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL5314796","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"It works by introducing an antigenic component that mimics the pathogen, thereby activating the immune system to produce antibodies and memory cells, which can provide protection against future infections.","oneSentence":"BIMERVAX is designed to stimulate an immune response against specific pathogens or antigens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:58:11.300Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of diseases caused by specific pathogens (indication details pending clinical trials)"}]},"trialDetails":[{"nctId":"NCT06234956","phase":"PHASE2","title":"Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2023-06-08","conditions":"SARS CoV 2 Infection","enrollment":242},{"nctId":"NCT05981846","phase":"PHASE2","title":"A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2023-09-04","conditions":"SARS CoV 2 Infection, Influenza, Human","enrollment":279}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BIMERVAX","genericName":"BIMERVAX","companyName":"Hipra Scientific, S.L.U","companyId":"hipra-scientific-s-l-u","modality":"Biologic","firstApprovalDate":"","aiSummary":"BIMERVAX is designed to stimulate an immune response against specific pathogens or antigens. Used for Prevention of diseases caused by specific pathogens (indication details pending clinical trials).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}